Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of BCX7353 in HAE
NCT03472040Phase 3Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Feb 2018
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc.. Started Feb 2018; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT03472040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472040.